Merck (NYSE: MRK) reported Q2 EPS of $1.37, $0.33 better than the analyst estimate of $1.04. Revenue for the quarter came in at $10.9 billion versus the consensus estimate of $10.39 billion.
GUIDANCE:
Merck sees FY2020 EPS of $5.63-$5.78, versus the consensus of $5.31. Merck sees FY2020 revenue of $47.2-48.7 billion, versus the consensus of $47.3 billion.
* MERCK ANNOUNCES SECOND-QUARTER 2020 FINANCIAL RESULTS
* Q2 NON-GAAP EARNINGS PER SHARE $1.37
* Q2 GAAP EARNINGS PER SHARE $1.18
* Q2 EARNINGS PER SHARE ESTIMATE $1.04 -- REFINITIV IBES
DATA
* COMPANY NARROWS AND RAISES 2020 FULL-YEAR REVENUE RANGE TO
BE
BETWEEN $47.2 BILLION AND $48.7 BILLION
* COMPANY NARROWS AND RAISES 2020 FULL-YEAR GAAP EPS RANGE
TO BE
BETWEEN $4.58 AND $4.73
* QTRLY KEYTRUDA SALES GREW 29% TO $3.4 BILLION
* NARROWS AND RAISES 2020 FULL-YEAR NON-GAAP EPS RANGE TO BE
BETWEEN $5.63 AND $5.78
* SECOND-QUARTER 2020 WORLDWIDE SALES WERE $10.9 BILLION, A
DECREASE OF 8%
* Q2 REVENUE VIEW $10.39 BILLION -- REFINITIV IBES DATA
* QTRLY JANUVIA / JANUMET SALES $1.34 BILLION VERSUS $1.44
BILLION
REPORTED LAST YEAR
* QTRLY GARDASIL / GARDASIL 9 SALES $656 MILLION VERSUS $886
MILLION REPORTED LAST YEAR
* FY2020 EARNINGS PER SHARE VIEW $5.31, REVENUE VIEW $47.33
BILLION -- REFINITIV IBES DATA
* V591 IS CURRENTLY IN PRECLINICAL DEVELOPMENT AND CLINICAL
STUDIES ARE PLANNED TO START IN Q3
* V590 IS CURRENTLY IN PRECLINICAL DEVELOPMENT AND CLINICAL
STUDIES ARE PLANNED TO START THIS YEAR.
* IN Q2, ESTIMATED OVERALL NEGATIVE IMPACT OF COVID-19
PANDEMIC TO
MERCK'S REVENUE WAS APPROXIMATELY $1.6 BILLION
* FOR 2020, NOW EXPECTS UNFAVORABLE IMPACT TO REVENUE OF
ABOUT
$1.95 BILLION (EXCLUDING IMPACT OF FOREIGN EXCHANGE) DUE TO
COVID-19 PANDEMIC
«Después de nada, o después de todo/ supe que todo no era más que nada.»
ALT, la vacuna covid que entre hace unos días, ayer +15% y ahora en pre lleva un 8% más. . No he visto news por el momento que lo justifique. Puede ser que vayan a recibir financiación USA A parte del PT de $80 q le ha dado Piper
ina rejects charges that hackers linked to its government targeted Moderna (NASDAQ:MRNA) to steal data related to research on a coronavirus vaccine. Citing an unnamed U.S. security official, Reuters reported yesterday that Chinese hackers targeted the U.S. biotech firm earlier this year. Moderna said it had been in contact with the FBI and was made aware of the suspected "information reconnaissance activities" by a hacking group mentioned in last week's Justice Department indictment, where two Chinese nationals were accused of spying on the U.S., including three unnamed U.S.-based targets involved in medical research to fight COVID-19. The two other unnamed medical research companies mentioned in the Justice Department indictment are described as biotech companies based in California and Maryland - descriptions that could fit Gilead Sciences (NASDAQ:GILD) and Novavax (NASDAQ:NVAX).
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Net income: ($3,339M) (-277.6%); non-GAAP net income: $1,400M (-36.2%); EPS: ($2.66) (-281.0%); non-GAAP EPS: $1.11 (-35.5%).
2020 guidance: Product sales: $23.0B - 25.0B from 21.8B - 22.2B; EPS: $0.83 - 2.23 from $5.15 - 5.55; non-GAAP EPS: $6.25 - 7.65 from $6.05 - 6.45
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#123598
Re: Farmas USA
Tarde Roja sangre...
De momento mantendre cash para imtemtar cazar oportunidades en farmas y alguna no farma. Un paquete de GE ha caido.
A ver que hace Nvax ya que entiendo que deberia de empezar a calentar motores para la Phase1.
#123599
Re: Farmas USA
Bastante liado, además de lo de hoy me he metido en KODAK y cometiendo un error no del todo por mi culpa, pensado que entraba para hoy y es para el viernes que viene. El primer vencimiento que aparecía, en vez de lo normal, era el siguiente. En fin. Parece que se endereza la cosa. AMRN muy de reojo y como el culo de nuevo. Se ha comido lo de ayer con creces.
